Effect of tamoxifen on the coronary vascular reactivity of spontaneously hypertensive female rats

Brazilian Journal of Medical and Biological Research

Volumn 44, Issue 8, 2011, Pages 786-792

  Borgo, M V ^a   Lopes, A B ^a   Gouvea S A ^a   Romero, W G ^a   Moyses, M R ^a   Bissoli, N S ^a   Abreu, G R ^a  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

Coronary; Estrogen; Hypertension; Menopause; Tamoxifen

Indexed keywords

TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; DRUG RESPONSE; FEMALE; MEAN ARTERIAL PRESSURE; MENOPAUSE; NONHUMAN; OVARIECTOMY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASOCONSTRICTION; VASODILATATION;

RATTUS;

EID: 84860422770     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2011007500099     Document Type: Article

References (39)

1. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: an age-old debate. Hypertension 2008; 51: 952-959.
2. Yang XP, Reckelhoff JF. Estrogen, hormonal replacement therapy and cardiovascular disease. Curr Opin Nephrol Hypertens 2011; 20: 133-138.
3. Wuest JH Jr, Dry TJ, Edwards JE. The degree of coronary atherosclerosis in bilaterally oophorectomized women. Circulation 1953; 7: 801-809.
4. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523-534.
5. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-613.
6. Moriarty K, Kim KH, Bender JR. Minireview: estrogen receptor-mediated rapid signaling. Endocrinology 2006; 147: 5557-5563.
7. Li L, Hisamoto K, Kim KH, Haynes MP, Bauer PM, Sanjay A, et al. Variant estrogen receptor-c-Src molecular interdependence and c-Src structural requirements for endothelial NO synthase activation. Proc Natl Acad Sci U S A 2007; 104: 16468-16473.
8. Prakash YS, Togaibayeva AA, Kannan MS, Miller VM, Fitzpatrick LA, Sieck GC. Estrogen increases Ca2+ efflux from female porcine coronary arterial smooth muscle. Am J Physiol 1999; 276: H926-H934.
9. Grainger DJ, Weissberg PL, Metcalfe JC. Tamoxifen decreases the rate of proliferation of rat vascular smoothmuscle cells in culture by inducing production of transforming growth factor beta. Biochem J 1993; 294: 109-112.
10. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046-1051.
11. Miller VM, Li L, Sieck GC. Endothelium-dependent effects of estrogen on vasomotor tone. Consequences of nongenomic actions. Vascul Pharmacol 2002; 38: 109-113.
12. White RE, Darkow DJ, Lang JL. Estrogen relaxes coronary arteries by opening BKCa channels through a cGMPdependent mechanism. Circ Res 1995; 77: 936-942.
13. Burger HG. Selective oestrogen receptor modulators. Horm Res 2000; 53 (Suppl 3): 25-29.
14. Couldwell WT, Weiss MH, DeGiorgio CM, Weiner LP, Hinton DR, Ehresmann GR, et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 1993; 32: 485-489.
15. Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin- Boes G, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006; 7: 633-643.
16. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115: 860-864.
17. Ek RO, Yildiz Y, Cecen S, Yenisey C, Kavak T. Effects of tamoxifen on myocardial ischemia-reperfusion injury model in ovariectomized rats. Mol Cell Biochem 2008; 308: 227-235.
18. Potts JT, McKeown KP, Shoukas AA. Reduction in arterial compliance alters carotid baroreflex control of cardiac output in a model of hypertension. Am J Physiol 1998; 274: H1121- H1131.
19. van Gorp AW, Schenau DS, Hoeks AP, Boudier HA, de Mey JG, Reneman RS. In spontaneously hypertensive rats alterations in aortic wall properties precede development of hypertension. Am J Physiol Heart Circ Physiol 2000; 278: H1241-H1247.
20. Doring HJ. The isolated perfused heart according to Langendorff technique - function - application. Physiol Bohemoslov 1990; 39: 481-504.
21. Figtree GA, Webb CM, Collins P. Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism. J Pharmacol Exp Ther 2000; 295: 519-523.
22. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res 2002; 53: 688-708.
23. Thorin E, Pham-Dang M, Clement R, Mercier I, Calderone A. Hyper-reactivity of cerebral arteries from ovariectomized rats: therapeutic benefit of tamoxifen. Br J Pharmacol 2003; 140: 1187-1192.
24. Simon T, Boutouyrie P, Simon JM, Laloux B, Tournigand C, Tropeano AI, et al. Influence of tamoxifen on carotid intimamedia thickness in postmenopausal women. Circulation 2002; 106: 2925-2929.
25. Dickhout JG, Lee RM. Blood pressure and heart rate development in young spontaneously hypertensive rats. Am J Physiol 1998; 274: H794-H800.
26. O'Malley CA, Hautamaki RD, Kelley M, Meyer EM. Effects of ovariectomy and estradiol benzoate on high affinity choline uptake, ACh synthesis, and release from rat cerebral cortical synaptosomes. Brain Res 1987; 403: 389-392.
27. Liu CC, Kuo TB, Yang CC. Effects of estrogen on genderrelated autonomic differences in humans. Am J Physiol Heart Circ Physiol 2003; 285: H2188-H2193.
28. Du XJ, Riemersma RA, Dart AM. Cardiovascular protection by oestrogen is partly mediated through modulation of autonomic nervous function. Cardiovasc Res 1995; 30: 161-165.
29. Skrzypiec-Spring M, Grotthus B, Szelag A, Schulz R. Isolated heart perfusion according to Langendorff-still viable in the new millennium. J Pharmacol Toxicol Methods 2007; 55: 113-126.
30. Moyses MR, Barker LA, Cabral AM. Sex hormone modulation of serotonin-induced coronary vasodilation in isolated heart. Braz J Med Biol Res 2001; 34: 949-958.
31. Santos RL, Abreu GR, Bissoli NS, Moyses MR. Endothelial mediators of 17 beta-estradiol-induced coronary vasodilation in the isolated rat heart. Braz J Med Biol Res 2004; 37: 569-575.
32. Luscher TF, Boulanger CM, Dohi Y, Yang ZH. Endotheliumderived contracting factors. Hypertension 1992; 19: 117-130.
33. Jensen EV, Suzuki T, Numata M, Smith S, DeSombre ER. Estrogen-binding substances of target tissues. Steroids 1969; 13: 417-427.
34. Nirmala PB, Thampan RV. Ubiquitination of the rat uterine estrogen receptor: dependence on estradiol. Biochem Biophys Res Commun 1995; 213: 24-31.
35. Hutchison SJ, Chou TM, Chatterjee K, Sudhir K. Tamoxifen is an acute, estrogen-like, coronary vasodilator of porcine coronary arteries in vitro. J Cardiovasc Pharmacol 2001; 38: 657-665.
36. Tsang SY, Yao X, Chan HY, Chan FL, Leung CS, Yung LM, et al. Tamoxifen and estrogen attenuate enhanced vascular reactivity induced by estrogen deficiency in rat carotid arteries. Biochem Pharmacol 2007; 73: 1330-1339.
37. Wickman G, Vollrath B. Effects of tamoxifen on oxyhemoglobin- induced cerebral vasoconstriction. Eur J Pharmacol 2000; 390: 181-184.
38. Tsang SY, Yao X, Chan FL, Wong CM, Chen ZY, Laher I, et al. Estrogen and tamoxifen modulate cerebrovascular tone in ovariectomized female rats. Hypertension 2004; 44: 78-82.
39. Controle do câncer de mama: documento do Consenso. http://www.inca.gov.br/publicacoes/Consensointegra.pdf. Accessed August 1, 2010.